by Crestone, Inc. | Jun 3, 2017 | Events
Crestone presents Phase 1 data from single and multiple ascending dose clinical trials with CRS3123, at the ASM Microbe Meeting in New Orleans. CRS3123 is a drug candidate in development for the treatment of C. difficile infections. Learn More: Phase I Trial to...
by Crestone, Inc. | May 17, 2017 | Events
Crestone, Inc. presents at the NTMir Patient and Provider Conference in Dallas, TX. Poster: Optimization and Lead Selection of Benzothiazole Amide Analogs toward a Novel Antimycobacterial Agent
by Crestone, Inc. | Sep 8, 2015 | Press Releases
Phase II SBIR Grant: “Optimization and Lead Selection of Novel Antimycobacterial Agents” InfoData Agency:Department of Health and Human Services Branch:National Institutes of Health Contract:2R44GM110848-02 Agency Tracking Number:R44GM110848 Amount:$1,477,487.00...
